PMID- 9924200
OWN - NLM
STAT- MEDLINE
DCOM- 19990421
LR  - 20190709
IS  - 0022-0795 (Print)
IS  - 0022-0795 (Linking)
VI  - 160
IP  - 2
DP  - 1999 Feb
TI  - Molecular forms of circulating adrenomedullin in patients with congestive heart 
      failure.
PG  - 297-303
AB  - In the biosynthesis of adrenomedullin (AM), an intermediate form, 
      AM(1-52)-glycine-COOH (iAM), is cleaved from proAM and subsequently processed to 
      a biologically active mature form, AM(1-52)-NH2 (mAM), by enzymatic amidation. We 
      recently reported that immunoreactive AM in human plasma consists of mAM and iAM. 
      To clarify the pathophysiological roles of mAM and iAM in heart failure, we 
      established an assay method to specifically detect mAM, and we determined the 
      plasma concentrations of mAM and iAM in 68 patients with congestive heart failure 
      (CHF). The plasma mAM concentrations of the CHF patients classified as being 
      class I or II of New York Heart Association (NYHA) functional classification were 
      significantly greater than those of the 28 healthy controls, and a further 
      increase was noted in the class III or IV patients. Similar increases in plasma 
      iAM were also observed in these patients compared with controls. The increased 
      plasma mAM and iAM in 12 patients with exacerbated CHF were significantly reduced 
      by treatment of their CHF for 7 days. In addition, the plasma concentrations of 
      both mAM and iAM were significantly correlated with pulmonary capillary wedge 
      pressure, pulmonary artery pressure, right atrial pressure, cardiothoracic ratio, 
      heart rate, and the plasma concentrations of atrial and brain natriuretic 
      peptides in the CHF patients. Thus the plasma concentrations of both mAM and iAM 
      were increased progressively in proportion to the severity of CHF. These results 
      suggest that, though the role of iAM remains to be clarified, mAM acts against 
      the further deterioration of heart failure in patients with CHF.
FAU - Hirayama, N
AU  - Hirayama N
AD  - First Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, 
      Kiyotake, Miyazaki 889-1692, Japan.
FAU - Kitamura, K
AU  - Kitamura K
FAU - Imamura, T
AU  - Imamura T
FAU - Kato, J
AU  - Kato J
FAU - Koiwaya, Y
AU  - Koiwaya Y
FAU - Tsuji, T
AU  - Tsuji T
FAU - Kangawa, K
AU  - Kangawa K
FAU - Eto, T
AU  - Eto T
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 0 (Biomarkers)
RN  - 0 (Peptides)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 148498-78-6 (Adrenomedullin)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Adrenomedullin
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Atrial Natriuretic Factor/blood
MH  - Biomarkers/blood
MH  - Female
MH  - Heart Failure/*blood/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptides/*blood
MH  - Precipitin Tests
MH  - Pulmonary Wedge Pressure
MH  - Statistics, Nonparametric
EDAT- 1999/01/30 00:00
MHDA- 1999/01/30 00:01
CRDT- 1999/01/30 00:00
PHST- 1999/01/30 00:00 [pubmed]
PHST- 1999/01/30 00:01 [medline]
PHST- 1999/01/30 00:00 [entrez]
AID - 10.1677/joe.0.1600297 [doi]
PST - ppublish
SO  - J Endocrinol. 1999 Feb;160(2):297-303. doi: 10.1677/joe.0.1600297.